

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Jazz Pharmaceuticals (solriamfetol) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • British Lung Foundation • Muslim Council of Britain • Narcolepsy UK • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • The Brain Charity • The Sleep Council <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Respiratory Technology & Physiology • Association of British Neurologists • Association of Respiratory Nurse Specialists • British Association of Neuroscience Nurses • British Geriatrics Society • British Neuropathological Society • British Neuropsychiatry Association • British Sleep Society • British Society of Dental Sleep Medicine • British Thoracic Society • Institute of Neurology • National Heart and Lung Institute • Primary Care and Community Neurology Society • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord-UK (methylphenidate) • Aurobindo Pharma - Milpharm (modafinil) • BioProjet (pitolisant hydrochloride) • Flynn Pharma (dexamphetamine, methylphenidate) • Generics UK T/A Mylan (methylphenidate) • Janssen-Cilag (methylphenidate) • Martindale Pharma (dexamphetamine) • Novartis Pharmaceuticals UK (methylphenidate)

Stakeholder list for solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [I1602]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Sleep medicine section • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Nottingham West CCG • NHS Tameside & Glossop CCG • Welsh Government 	<ul style="list-style-type: none"> • Sandoz (methylphenidate,) • Shire Pharmaceuticals Limited (methylphenidate) • Teva Pharma (modafinil) • UCB Pharma (sodium oxybate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Association for Lung Research • British Neurological Research Trust • Cochrane Common Mental Disorders Group • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.